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PREFACE 
This report is a review of the literature concerning recombinant DNA, 
the process of taking genes from one organism and splicing them into the 
genes of another different kind of organism. First, the mechanics of the 
process are explained. Then the medical, industrial, and agricultural 
products being synthesized by recombinant DNA are enu..merated. Other areas 
of research which use the methodologies of recombinant DNA research are 
discussed. 
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INTRODUCTION TO RECOMBINANT DNA 
Recombinant DNA, gene-splicing, and genetic engineering are all terms 
for one controversial and exciting technology of molecular biology. Re-
combinant DNA is the process of taking genes from one organism and splic-
ing them into the genes of another different kind of organism which can 
result in the modification of the organism. 1 Until the development of 
this technique, scientists were limited to working with traits found natu-
rally in a species' genetic repertoire. Now they have domesticated a 
variety of life, microorganisms, that might serve humanity in efficient 
ways because of its simplicity and capacity for reproducing exact repli-: 
cas of itself. 
The work of great scientists such as Anthony von Leeuwenhoeck, in-
ventor of the microscope; Robert Hooke, discoverer of the cell; Gregor 
Mendel, meticulous researcher who wrote the laws of heredity; Boodle and 
Tatum, who identified DNA as genetic material; Francis Crick and James 
Watson, discoverers of the structure of the DNA molecule; and Jacques 
Monad and Francois Jacob, Researchers who discovered operon genes; made 
contributions which led to the pioneering experiment on recombinant DNA 
in 1973. Stanley Cohen and Annie Chang of Stanford University, and 
Herbert Boyer and Robert Helling of the University of California at San 
Francisco inserted a gene that makes Salmonella resistant to the antibi-
. . . 1· . h ' · 2 otic streptomycin into E. co i whic consequently oecame resistant. 
l 
Recombinant DNA is not something which has never before occurred; 
the change of genetic material naturally occurs in sexual reproduction, 
transformation in bacteria, and transduction by viruses. 3 It may have 
2 
even occurred naturally between certain bacteria and humans because some 
bacteria harbor genes similar to the human genes that regulate the pro-
4 
duction of chorionic gonadotropin. - But the Recombinant DNA methodology 
is very different in two ways from natural transplantation. One differ-
ence is that recombination may occur between widely different species, 
and the genetic information may be very specific and in small segments 
coded for a known effect. A second way that the methodologies are unlike 
is that the vehicle that carries the segment from the donor organism to 
the host allows. for the donor segment to be spliced together and reas-
sembled in a structure that can be inserted into the host. 5 
The recombinant DNA methodology allows several important opportuni-
ties to manipulate molecular genetic systems and will be explained in 
some detail in this report. First, it allows very long and complicated 
continual sets of genomes to be fractionated into much smaller functional 
units and placed in single cells where the study of the function control-
led by one genetic expression may be done. Second, by isolating one cell 
in a culture with the desired fragment of genetic information, it is pos-
sible to grow colonies of cells from it, all of which will have the 
desired component. Therefore, the component will be greatly amplified 
without any deterioration in the fidelity of its expression. Third, the 
products of the gene fragment's expression can be separated from the 
natural environment where they are frequently victims of the cells own 
mechanisms for maintaining specified concentrations of a product. Fourth, 
new genetic combinations can be created which make materials advantageous 
6 to human purposes. 
3 
After the process of Recombinant DNA is explained, the products being 
produced by it will be listed and the other areas of research which use 
it will be explored. The products being produced by Recombinant DNA fall 
into three broad categories, agricultural, industrial, and medicinal. In 
agriculture, one of the goals is to transfer the genes for nitrogen-
fixation into the cells of plants like corn and wheat which are now con-
sumers of fertilizers. In industry, there are many goals, such as improv-
ing the efficiency of fennentation processes, using the capacity of 
microorganisms to metabolize crude petroleum and metals, and using specific 
enzymes produced by bacteria in petrochemical syntheses and for specific 
bioconversion steps. In medicine, the greatest progress seems to be tak-
ing place. Substances such as human-growth hormone, insulin, interferon, 
and somatostatin are being produced by bacteria. 7 When products are 
synthesized with Recombinant DNA methodology, the cost of their produc-
tion generally decreases because the amount of energy consumed in the 
processes is less. Also pollution is not a problem because only natural 
8 
products are excreted. 
Other areas of research which use some of the Recombinant DNA meth-
odology include nucleotide sequencing, evolution, physical mapping of 
chromosomes, gene regulation, differentiation, prenatal examination of 
human genes, gene therapy, and ecology. Recombinant DNA has even caused 
scientists to question old genetic dogmas, such as the alikeness of genes 
in different organisms and the shape of the DNA molecule. 
FOOTNOTES 
1 s. Begley and P. Abramson, "The DNA Industry; Re.combinant Technol-
ogy," Newsweek (Aug. 20, 1979), p. 53. 
2M. Clark, "The Miracles of Spliced Genes (Recombinant DNA)," 
Newsweek (March 17, 1980), p. 63. 
3w. N. Hubbard, "The Industrial Potential of Recombinant DNA Tech-
nology (address, Jan. 24, 1980) ," Vital Speeches (March 11, 1980), p. 342. 
4 Peter Gwynne, "Caution: Gene Transplants," Newsweek (March 21, 
1977) I P• 58. 
5 
Hubbard, p. 342. 
7Ibid. 
8M. Sheils, "How Molecular Biology is Spawning an Industry (commer-




A GENERAL DESCRIPTION OF THE PROCESS OF 
RECOMBINANT DNA 
The mechanics of the process of recombinant DNA began with the dis-
covery of restriction enzymes in 1971. 1 In general, scientists take donor 
DNA, which is DNA from cells or DNA chemically synthesized in a laboratory, 
use restriction enzymes to cut it at specific points, insert the desired 
fragments into the DNA of a carrier of vehicle, which is a bacterial plas-
mid or a virus, and then place the carrier into a host, usually.;. coli. 
The constellation of recombinant DNA techniques for placing and maintain-
ing a new gene in bacteria is called cloning.- It is defined as the isola-
tion of a specific new DNA sequence in a single organism that proliferates-
to form a population of identical descendants, a clone. 2 
The problem, which the mechanics of this process are being developed 
to solve, can be broken down into three parts. First, the correct struc-
tural sequence of DNA must be located or created. Second, it must be 
placed in bacteria in such a way that it will be maintained as the bac-
teria grow and divide. Third, the surrounding information in the DNA must 
be manipulated so that the regulatory commands can be modified to direct 
the spliced sequence to produce protein. Once the spliced gene expresses 
itself, and protein is made, further changes in it or modifications in 
the bacteria are sometimes needed to obtain proten in large enough amounts 
3 
to be useful. 
5 
6 
There are several ways of getting the donor DNA. Restriction endo-
nucleases have the ability to scan a long thread of DNA and to recognize 
particular short sequences as landmarks at which to cut the molecule 
apart. Over forty of these have been discovered. Each one recognizes 
different landmarks, therefore, each one breaks up any given DNA into a 
characteristic set of short pieces which can be isolated by length. 4 
Herbert Boyer found that some of these enzymes produce staggered cuts in 
double strands of DNA so single-stranded ends are produced at each end 
of the fragments. Since all the fragments produced by a given enzyme 
have the same self-complementary end, a single fragment can form a circle 
by base-pairing or can combine with another fragment to produce a dimer. 
If the second fragment is from a different DNA source, a recombinant 
molecule is produced. DNA ligase is the annealing enzyme, which glues 
5 
the ends together. 
Even with the restriction endonucleases, there is a problem sometimes 
with getting a needed DNA fragment and placing only that fragment into a 
bacterium. Consequently, a second method for obtaining donor DNA has 
been developed. By knowing the amino acid sequence of a protein, the 
base sequence can be predicted, and a corresponding DNA molecule can be 
chemically synthesized. 6 Several other ways of sequencing DNA have been 
developed, and genes can be made in laboratories. 
Structural gene infonnation also exists in continuous form on mes-
senger RNA (mRNA). Since different cells specialize in the synthesis of 
different proteins, appropriate tissues will contain the desired mRNA 
along with other messengers for the common proteins made by all cells. 
In order to convert desired structural information from a cell's mRNA 
into DNA to be cloned, a special enzyme, reverse transcriptase, is used 
7 
to copy a single strand of RNA to make a complementary strand of DNA 
(cDNA). This strand of cDNA is used to make a second strand of DNA, and 
the resulting double-stranded cDNA fragments are copies of the messengers 
that were present in the tissue. This cDNA can be cloned, but there are 
two problems with it, the detection of clones with the sought-after 
structural DNA fragment and the providing of appropriate signals. 7 
The carriers in the Recombinant DNA process must be capable of being 
identified as actually containing the desired DNA fragment, must have a 
marker that allows them to be identified after they are placed in a host 
8 
cell, and must replicate in the host. Bacterial plasmids and viruses 
are the vehicles used. They strain the definition of life because they 
are negentropic, which means they expand energy to keep themselves in 
9 
order. Plasmids carry only a few genes of their own, are separate from 
the main set of bacterial genes, and are maintained in several copies in-
. b . 10 side acteria. The Col El plasmid is the most popular one. If foreign 
DNA is inserted at the Eco RI site, the recombinant plasmid can be de-
db . d d h 'b' . 1· · ll tecte ecause it oes not pro uce t e anti iotic co icin. Donald 
Helinski at the University of California at San Diego has developed two 
unique fonns of this plasmid, Col El-kan and Col El-trp. Col El-kan con-
fers resistance to the antibiotic kanomycin, therefore, it is less safe 
than Col-El-trP which has a nutritional marker. Only bacteria with it 
can grow in culture plates lacking the amino acid tryptophan. Neither 
12 
one of these plasmids is a disabled vector. 
Viruses have from ten to fifty genes of their own and can often 
13 
carry other new DNA segments in place of some of their own. Frederick 
R. Blattner and Bill G. Williams of the University of Wisconsin have engi-
neered bacteriophages, charon lambda phages, as vectors for cloning. 14 
8 
Lambda is particularly well suited as a vehicle because a third of its 
D~A, a block in the middle of its genome, can be replaced without it los-
ing its ability to grow lytically. Charon 3 and 4, both mutations of 
larnbd h ld 1 . f f . 15 a, can o arge pieces o oreign DNA. 
16 
ing can be monitored with dye indicator plates. 
The success of the splic-
Cloning with lytic 
phages has natural advantages. One is that the phage and sensitive bac-
teria must repeatedly come togehter for replication. Also their chimeric 
DNA is delivered to the experimenter in a package. And since the phage 
and bacterium coexist only briefly, the cloned fragment need not be com-
'bl ' h th b ' I ab l' f d d ' • d 17 pati e wit e acterium s met o ism or an exten e time perio. 
One problem with phage vectors is that they may lysogenize rather than 
kill the cell. The charon 3 and 4 phages have been engineered to kill 
cells so efficiently that only one surviving cell with the foreign gene 
can be found during the production of 1000 billion phages. Since large 
nmnbers of phages can be grown in a small volume of culture medium, less 
18 
spillable liquid must be handled. 
Vector engineering has many objectives. They are to alter the dis-
tribution of restriction sites and eliminate sites in essential genome 
regions, to clone a variety of sizes of DNA fragments, to clone with more 
than one restriction enzyme, to be able to indicate by plaque type whether 
or not a phage has incorporated a DNA fragment, to clone with minimal 
manipulation, to control the transcription of cloned fragments from vec-
tor promoters, to grow vectors and clones to high yield, to recover clon-
d d ' l d 'b - ' 1 · 1 · 19 e DNA rea i y, an to contri ute to bio ogica containment. 
Caulimoviruses, such as CAMV Pahlia mosaic, and strawberry etched 
ring, are the plant viruses known to contain DNA. Therefore, they may 
become transducing vehicles for the introduction of foreign DNA fragments 
9 
20 
into plant cells. Defective derivatives of the DNA of the tumor viruses 
SV40 and polynoma are possible vehicles but are currently banned-because 
they have been found to cause cancer in laboratory animals. 21 
Once a chosen DNA fragment has been inserted into a carrier, then the 
vehicle must be inserted into the host where it can replicate. The host 
must be capable of having its cell wall altered so the carrier can pene-
d . , . . 22 trate an survive tne insertion. This is accomplished by using a dilute 
solution of calcium chloride to render the bacteria permeable. 23 
~· coli is the most common host used although Saccharomyces cerevisiae, 
Neurospora crassa, Bacillus subtilis, and Pseudomonas have been suggested. 
Roy Curtiss III at the University of Alabama Medical Center disa:rmed E. 
coli to fit a pre-determined set of safety criteria. The X-1776 strain 
has two mutations which make it nearly impossible for the bacteria to 
colonize the intestinal tracts of animals. They cannot make diarninopi-
melic acid or colanic acid, substances required respectfully in the making 
of the cell wall and in holding the cell together. They are also temper-
0 ature sensitive (self-destruct at 42 C) and are killed when exposed to 
ultraviolet light (sunlight). The bacteria cannot make thymine, there-
fore, cannot pass genes onto healthy outsiders during conjugation. They 
cannot conjugate with most other bacteria or be infected by most bacter-
ial viruses. They cannot survive in human serum including that of cancer 
24 
patients and are destroyed by common household detergents. 
Once the vehicle has been inserted into the host, the spliced gene 
must be able to be turned on, a process called transformation. Bacteria 
have four signals which must be both efficient and optimally placed. One 
signal starts the synthesis of a mRNA and is located immediately in front 
of the segment of DNA to be transcribed. A second signal functions as 
10 
part of the mRNA to tell the bacterial translating machine where to start. 
The other two signals are stop signals for transcription and transla-
tion.25 These signals can be cut out with restriction enzymes and placed 
wherever they are needed. 
The cells which are transformed can be identified if the vehicle pro-
. d h b · d · 26 vi es a property t e acteria nee to survive. The identification of 
the desired clone can be done after the cells have formed colonies. One 
way of identifying the desired colony is by doing hybridization test. If 
the mRNA from which the cDNA is made is pure, the host colonies are grown 
on a disk of cellulose nitrate paper. The bacterial cells are then brok-
en open where they lie, and the released DNA is fixed to the paper, 
denatured, and reannealed to radioactive RNA. Only the DNA st.rands whose 
sequence matches the mRNA become radioactive. Since the location of the 
desired DNA is known, bacteria which contain the modified sequence may 
be obtained from replica colonies and cloned. 27 
If the mRNA is not pure, there are several ways to detect the desir-
ed colony. One way is to let antibodies detect thE· detailed shape of the 
corresponding protein molecule. Another way is to make the mRNA function 
in a test tube by adding the machinery needed for translation and radio-
active amino acids. Then antibodies can recognize the desired radioactive 
protein. A third method is to take the cDNA and hybridize it to a mixture 
of RNA's. Only the RNA that matches the desired sequence will anneal to 
it, therefore, no longer functioning in translation. The desired DNA is 
. . . . . 28 
recognized by its ability to block the synthesis of the desired protein. 
Several problems concerning the yield of the products occur and must 
be solved. Often the new proteins are broken down in the bacterial cells 
because their structure is such that enzymes normally present in the 
11 
bacteria can digest them. Ways must be found to stabilize the proteins 
either by removing these enzymes by embedding the new proteins in hybrid 
proteins to protect them, or by secreting them from the cell. Messenger 
RNA molecules are often unstable within bacterial cells. Therefore, modi-
fication in their structure and in the cells can make them more effective 
and lead to increased protein synthesis. Third, the number of copies of 
the desired gene within each cell must be increased so more product can 
b h . d 29 e synt es1ze. 
FOOTNOTES 
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THE PRODUCTS BEING SYNTHESIZED BY RECOMBINANT DNA 
Agricultural, industrial, and medical researchers are investigating 
the use of DNA techniques to synthesize valuable products. Anything that 
is basically a protein will be makable in unlimited quantities. Especial-
ly important will be the production of proteins which cannot be obtained 
in useful forms from animals. Recombinant DNA microorganisms may eventu-
ally produce 10 to 20 percent of all the organic compounds required by 
industry, such as petrochemical derivates from plastics to pigments. 
Genex, a Bethesda, Maryland, firm has identified 107 existing products 
that can be manufactured in 5 to 20 years with recombinant DNA. 1 Five 
products--human growth hormone, somatostatin, and A and B chains of human 
insulin, human proinsulin, and thymosinalpha-1~-have been approved for 
2 
large-scale culture by Genentech. Only one artificially altered genetic 
material, a corn variety, has been approved to be released into the envi-
3 ronment. DNA ligase is produced by N. E. BioLabs of Beverly, Massachusetts, 
and is being sold to scientists. 4 Many restriction enzymes are also 
available. 
More medically important products are being synthesized than ones in 
the other two research areas. The first protein made was somatostatin. 
It was followed by insulin, human growth hormone, and interferon. 5 
Somatostatin is a rnanunalian neurohormone secreted by the hypothala-
mus in trace amounts. It inhibits the release by the pituitary gland of 
14 
15 
honnones that regulate body growth and glucagon and insulin production. 
Therefore, it may be useful in the treatment of diabetes, pancreatitis, 
6 
and acromegaly, a disease of abnormal bone growth. 'When somatostatin 
was first isolated, it took half a million sheep brains to produce five 
milligrams of it. With recombinant DNA, Herbert Boyer, Aruther Riggs of 
the City of Hope Medical Center, and Wylie Vale of the Salk Institute, 
respectively, required only two gallons of bacterial culture to produce 
five milligrams of it. 7 The researchers choose somatostatin as the first 
substance to produce with recombinant DNA because of its small size (four-
teen known amino acids), sensitive radioimmune and biological assays, 
and intrinsic biological interest. 8 They synthesized the gene for 
somatostatin from its known amino acid sequence and linked it to the 
bacterial beta-galactosidase gene which can be recognized by!· coli. 
The genes were bridged by the nucleotides that code for methionine. The 
long chain was spliced into a plasmid vector that was picked up by!· 
coli and introduced into colonies. The chain was isolated from a colony 
and treated with cyanogen bromide which breaks it at methionine, therefore, 
f . . 9 reeing somatostatin. 
Insulin is produced by the cell in the Isles of Lar..gerhans in the 
pancreas and regulates the metabolism. Five percent of diabetics have 
11 . . th 1 d l d ' ' 1 · lO a ergic reactions to e current_y use catt e an swine insu in. If 
human insulin can be produced commercially with recombinant DNA, the risk 
of allergy or antibody-rejection by diabetics will be eliminated, the 
cost for diabetics will be less, and the problem of the shortage of ani-
11 
mal insulin will be solved. Insulin is a small hormone made of two 
chains, chain A, twenty amino acids long, and chain B, thirty amino acids 
long. These are initially part of a chain of 109 amino acids, 
16 
proinsulin. This chain folds up bringing the first and last segments to-
gether, and the central portion is cut out by an enzyme. The purpose of 
12 
this central portion is to align the two chains correctly. Two teams, 
one at the City of Hope Medical Center under the direction of Dr. Keirehi 
Itakura and the other at Genentech, Inc. , under the direction of David 
Goeddell have produced insulin with recombinant DNA. An artificial gene 
for each chain of insulin was spliced into a plasmid among a group of 
genes that bacteria switch on in the presence of lactose~ Each bacterium 
was induced to produce 100,000 molecules of either chain, then the chains 
were purified and combined. Ten to forty percent of the material formed 
th . h . 1 b d db 1 . 1· 13 e two appropriate c emica on s an ecame compete insu in. Prior 
to this final experiment, the chains were produced in separate bacteria 
and then combined, proinsulin was produced, and rat insulin was produced .. 
Human growth hormone is produced by the pituitary gland. It stimu-
lates the natural healing process and is used to treat pituitary dwarfism, 
stomach ulcers, and burn injuries. Currently it takes fifty pituitary 
glands from cadavers to supply enough hormone for one child suffering 
14 
from dwarfism for one year. Both human and rat growth hormone have 
been produced with recombinant DNA. Eighty percent of the gene was cop-
ied from mRNA, and the rest of it, a restriction enzyme site, was synthe-
sized. The gene was linked to a fragment of the trp D gene of E. coli in 
a plasmid vehicle. The fusion protein was synthesized at a high level, 
reacted specifically with antibodies to human growth hormone, and was 
abl . 1 · 15 st e in E. co i. There were three problems concerning the production 
of it by bacteria. One problem was finding a method to trim the hybrid 
protein into the desired hormone; another problem was handling large vol-
urnes of hormone-producing bacteria; and the third problem was getting FDA 
. 1· . 11 16 to use it c inica y. 
17 
Interferon was accidentally discovered in England in 195 7. It is 
a protein possessing both antiviral and antitumor properties. In large 
doses, it is effective against chicken pox, shingles, and Gennan measles 
viruses. It is used in cancer treatment because it seems to block cell 
division and in research on flu and colds. Currently it takes 65,000 
17 
pints of blood to get 100 mg of it, and it costs $75 per shot. The 
main problem that had to be overcome before it could be produced with re-
combinant DNA was getting enough mRNA for it since this is very rare. 
Human white blood cells were exposed to a virus, and the mRNA was extract-
ed from them and used to generate the gene. The gene was spliced into a 
plasmid which was taken up by E. coli. The bacteria produced human fibro-
blast interferon with all its nonnal properties. It is a protein, with-
stands acid treatment, reacts with antibodies that bind it, and is species 
specific. But it also had some properties that were different from human 
interferon. It was a larger molecule and did not have the sugars found 
on human interferon. The larger size may be due to a signal sequence 
that animal cells can cleave, but bacterial cells cannot. 18 Since this 
experiment, Biogen's Charles Weissman of the University of Zurich and 
. 19 Walter Gilbert of Harvard have produced human leucocyte interferon. 
Several other medically important substances have been produced with 
recombinant DNA. John D. Baxter of the University of California at San 
Francisco engineered the production of the mammalian pain-countering 
chemical beta-endorphin. It is naturally produced by the pituitary gland. 
Currently, it is being tested as a treatment for both depression and 
schizophrenia. The gene for mouse beta-endorphin was modified and con-
nected to a portion of the bacterial gene, beta-galactosidase, in a 
1 'd 20 p asmi. 
18 
Thymosin alpha-1, a honnone that stimulates the human immune system, 
is being produced by bacteria. It has shown promise in clinical trials 
21 
for the treatment of brain and lung cancer. 
Bethesda Research Labs has produced proline, an amino acid, in the 
first fonnal application of recombinant DNA to nutrition. It is used in 
livestock feed and intravenous feedings and may become a food supplement, 
therefore, decreasing the costly world food supply. A bacterial virus 
was the vehicle in this experiment. 22 
The largest protein that has been successfully expressed and recover-
23 
ed is ovalbumin from fowl. 
The recombinant DNA techniques hold promise for producing materials 
for vaccines against infectious diseases. They provide new opportunities 
for making large amounts of pure viral components and for redesigning 
viruses for use in live vaccines. Some advances have already occurred. 
Bacterial components implicated in diarrheal diseases and genes from in-
fluenza and hepatitis viruses have been produced. The G. D. Searle Com-
pany produces the flu virus antigen hemagglutinin with bacteria. 24 
Kenneth Murray of Edinburgh University has cloned the coat protein of 
the hepatitis B virus, 25 and an antibody against one chemical on the 
26 
surface of the malaria parasite has been produced. Genentech and the 
Department of Agriculture have cloned viruses needed to produce a vaccine 
. h . h . 27 against oof-ana-mout disease. Bacteria are also making individual 
subunits of disease-causing toxins. Toxins have been found to have two 
subunits, one is the enzyme that produces the detrimental effect and the 
other is the delivery component._ The delivery subunit may be a valuable 
vaccine material because it should induce an immune response without 
hanning the patient. Some bacteria are making the enzyme subunits so 
the toxins can be deactivated. 28 
19 
Recombinant DNA is also used in antibiotic research. Low producing 
organisms can be amplified so their product is in sufficient quantity to 
be examined as a possible medicine. Antibiotics can be produced in a 
non-destructive environment, and their concentrations in the culture med-
ium can be increased, therefore, decreasing their cost and widening their 
'lab' l' 29 avai 1 ity. 
There are four speculative possibilities for the future use of re-
combinant DNA in medicine. It can be used to identify very specific ac-
tion sites within parasitic organisms that cause tropical diseases. Then 
specific antibodies can be produced by transformed organisms. It could 
also be used to make highly specific antigens to protect whole popula-
tions. A male antifertility agent could be made. It would be an anti-
body against the contractile protein of the sperm tail that would not 
interfere with sperm maturation or affect the genetic information in the 
head. An antidote to drunkenness could be developed by providing medi-
cinally the alcohol dehydrogenase exhausted from the liver. 30 
Biotechnology or industrial processes based on biological systems 
is the growth business of the future. 31 It was started when General 
Electric's Ananda M. Charkrabarty created a multiplasmid super bug which 
can digest about two-thirds of the hydrocarbons in crude oil much fast-
er and more efficiently than other biodegradation systems. The genetic 
ability to digest petroleum is transmitted on plasmids. He induced di£-
£erent strains of Pseudomonas to conjugate in such a way that a recipient 
strain ended up with the hydrocarbon breakdown plasmids from three other 
strains. The by-products of the breakdown are the useful metabolic pro-
ducts, carbon dioxide, water, and protein which can become very useful. 32 
Other current experiments are projects to make alcohol from biomass 
20 
more economically or from manioc or cellulose, therefore, boosting its 
. 1 . 1 ub . f 1 · 33 potentia as a partia s stitute or gaso 1ne. Two approaches can be 
taken to this project. Either develop more efficient yeasts, which has 
been done, or use microorganisms as enzyme factories and then add enzymes 
directly to the substrate to produce the desired effect. 34 Another pro-
ject is to cut the production costs for chemicals like antifreeze by 
controlling reactions with bacterial enzymes. 35 This would save energy, 
increase the efficiency of the process, and decrease the need for oi1. 36 
Bacterial factories can be created for specific bioconversion steps such 
as those in steroid production that now are unobtainable for lack of 
bacteria with specific enzyme capacity. 37 Another project is to use the 
capacity of microorganisms to metabolize metals to increase the recovery 
of metals from lean ores by leaching with them. Industrialists also 
want to convert ethylene and propylene, basic petrochemical feedstocks, 
into their oxides and glycols for half price. Ethylene glycol is the 
main ingredient in antifreeze and propylene oxide is used in the produc-
tion of plastics. Bacteria can also be used to make specialty chemicals 
needed to produce dyes, detergents, flavor and perfume agents, lubricants, 
fertilizers, synthetic rubber and pesticides, to produce enzymes for food 
and animal feed, to produce gums to aid in the recovery of oil from 
played-out wells, to convert coal to natural gas, to distill whisky, and 
to metabolize margarine so that it will taste like butter. 38 
The need for a quantum increase in agricultural production has been 
recognized for a long time, but there is a ceiling imposed on it by the 
l ck f t . . . . . 39 a o gene ic variation in many crop species. The main objective of 
recombinant DNA in agriculture has been to create bacteria capable of 
nitrogen-fixation. Nitrogen is fixed naturally by the root nodule 
21 
bacteria, Rhizobia, of leguminous plants like soybeans. These bacteria 
harbor the nitrogen-fixing, NIF, genes which code for the nitrogenase 
proteins. A nitrogen-fixing recombinant of~- coli has been constructed 
by transferring the NIF segment of DNA from Klebsiella pneumoniae to~-
coli on a plasmid. There may be a need for the enzyme that catalyzes 
the transfonnation of molybdenum to a fonn suitable for insertion into 
nitrogenase and for enzymes that catalyze various membrane-associated 
reactions. 
40 
~- coli already has these support enzymes. If the plasmid 
that carries the NIF genes can be incorporated into the cells of plants 
like corn and wheat, they would be able to fix nitrogen, and our depend-
ence on the energy required to produce nitrogen fertilizers would de-
crease. Several techniques need to be developed before the incorporation 
can be done. These include developing some fonn of protection to prevent 
destruction by plant nucleases, stimulating the infected protoplast to 
produce a callus and subsequently sexually competent plants, and develop-
ing some fonn of protection to prevent oxygen inhibition of the nitro-
genase activity. Once solutions have been found, utilization will be 
through plant breeding techniques. 41 
Another use of recombinant DNA in agriculture is to transfer 
characteristics which determine resistance to pathogens into cells of 
42 
otherwise successful varieties of crop plants. If this can be done, 
the problems of toxicity and the use of pesticides and herbicides can 
b . 43 e avoided. Recombinant DNA is also being used to increase the ef-
ficiency of photosynthesis in order to get larger crop yields, to change 
the husks of grain plants to make them more resistant to cold or drought, 
44 
thereby, increasing their geographical range, and to circumvent the 
mating barrier between different species so that novel genetic systems 
45 
can be explored. 
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CHAPTER IV 
OTHER AREAS OF RESEARCH WHICH USE THE 
RECOMBINANT DNA TECHNOLOGY 
Because of the opportunities to manipulate molecular genetic systems, 
recombinant DNA is allowing scientists to re-examine old genetic dogmas. 
For example, bacterial genes have been found to be different from those 
of higher organisms. All the nitrogenous bases in their DNA are read by 
enzymes three by three and translated directly into amino acids. But in 
viral and mammalian DNA, elements of DNA that code for amino acids are 
separated by base sequences (intrans) that do not seem to get translated 
into any protein. The DNA bases are copied into a molecule of RNA which 
enzymes process. These enzymes cut the intrans out of the RNA and splice 
the remaining coding segments together. It is thought that these piece-
meal genes may have helped humans evolve since they can be shuffled more 
easily into new combinations which may change the character of a cell and 
1 
give the organism a selective advantage.-
A second dogma that has been re-examined is that of the shape of the 
DNA molecule. Its shape, a small percent of the time, is that of a zig-
zag that twists to the left instead of a smooth curve that twists to the 
right. The smooth spiral changes into this zigzag form at special base 
sequences. This change may occur when genes turn themselves off, and 
2 
some of these transformations may attract carcinogens and trigger cancer. 
The recombinant DNA methodology is currently leading to discoveries 
25 
26 
in still more areas of scientific research. For instance, by being able 
to reproduce isolated DNA segments in bacteria, scientists are being pro-
vided with enough DNA to detennine the exact nucleotide sequence. Being 
able to do this increases the knowledge of the language of the genetic 
code and provides instructions for chemists interested in synthesizing 
specific genes. The infonnation provided is also useful in studying evo-
lution because theories about mutation and selection can be explored by 
comparing the chromosomal sequences of closely and distantly related 
species. 3 Since scientists can synthesize DNA, they may create mutations 
and may eventually design specific mutations to be inserted into organ-
. h · 11 . 11 · 4 isms sot ey wi continua y exist. 
Isolated DNA segments ca~ be used to locate genes on original chroma-
sames, therefore, providing a physical map. A map can help scientists 
understand the coordination of gene expression by learning more about the 
5 
interaction of adjacent regions and the meaning of repeated sequences. 
The understanding of the regulation of gene expression is very important 
in research having to do with cancer and differentiation. To find the 
DNA region that is necessary to start the expression of a gene, the DNA 
can be trimmed until the gene no longer functions. 6 In one study with 
the lambda virus, the behavior of the genes was shown to depend on a re-
pressor molecule. Normally DNA sends instruction for protein synthesis 
with the aid of a transcribing enzyme. Depending on how the repressor 
is positioned within the control region of the DNA, it can either attract 
the transcribing enzyme, thereby, turning on the genES for viral repro-
duction in~- coli or deflect the transcribing enzyme, thereby, keeping 
7 
the genes turned off. 
Recombinant DNA methodology is valuable in testing hypotheses about 
27 
how genes control development. Scientists try to distinguish the control 
of protein production at the DNA-to-RNA step and at the RNA-to-protein 
8 
step in order to tell when a gene is first expressed. In this research, 
techniques from cancer studies are used because genes of tumor causing 
viruses that invade cells are virtually the same as genes that already 
inhabit the cell, and these viral genes have been cloned. 9 
The prenatal examination of human genes in amniotic fluid cells re-
quires tJ1e use of restriction enzymes. Del ta beta-thalassemia disease and 
trait can be identified by a special technique requiring them. After 
they fragment the DNA, and the segments are separated according to size, 
probes of radioactively labelled DNA segments of the same sequence as the 
beta-globin gene being studied are added. The probes bind specifically 
to the DNA segments containing pieces of the beta-globin gene DNA. Then 
the DNA-containing material is exposed to photographic paper. Since only 
the beta-globin bands appear, scientists can compare normal patterns with 
those from fetuses suspected of having delta beta-thalassemia known to 
be due to deletions of the beta-globin gene. Scientists have found that 
in delta beta-thalassemia, there is an absence of certain DNA segments 
that hydridize with the beta-globin gene and that if the beta-globin gene 
bands are present in a smaller number than normal in the material, the 
fetus is a trait carrier. In alpha-thalassemia fetuses, there is an 
absence of alpha-globin genes. Sickle-cell anemia is the next most likely 
d . d .f= 1 d . b ' ab 1 · . l lO can i ate ~or prenata etection ecause its DNA norma ity is <nown. 
Gene therapy which is the insertion of a properly functioning new 
gene into a cell or the repair of a defective gene, is also an offshoot 
of recombinant DNA methodology. W. French Anderson of the National Insti-
tute of Health injected genes prepared with recombinant DNA methods with 
28 
a micropipette directly into specific mouse cells growing in a laboratory 
tissue culture. In several instances, the .cells accepted the foreign 
material, either a viral gene for the enzyme thymidine kinase or the 
human beta-globin gene, and thirty generations later the genes were still 
functioning in the descendants. This type of research will allow scien-
tists to compare under identical conditions the operation of a gene when 
it is transplanted into different types of mammalian cells or the opera-
tion of different genes in one cell type. 11 
The first successful insertion of a selected gene into a living ani-
mal was done by Martin J. Cline, Howard Stang, Karen Mercoli, and Winston 
Salser. Using recombinant DNA methods, they isolated genetic material 
containing the gene that confers resistance to an anti-cancer drug from 
mice and inserted it into the bone marrow cells of other mice. The first 
spinoff of their research will probably come in cancer therapy. Cancer 
patients may be given the gene for resistance to the chemotherapy drug, 
methotrexate, in their bone marrow cells. Consequently, the drug will 
not harm healthy tissue or impair blood production. There are many prob-
lems with gene insertion that need to be solved, but thalassemia and 
sickle-cell anemia are targets for gene therapy. 12 
Ecologists may use recombinant DNA methodology to improve the ecol-
ogical balance of species. They would be able to do this because recombi-
nant DNA would enable humans to decrease their reliance on land devoted 
to crops and herds. This could be done if scientists can manipulate the 
genes of higher plants and animals. 13 
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CHAPTER V 
ASPECTS OF THE CONTROVERSY CONCERNING 
RECOMBINANT DNA 
The debate over recombinant DNA started in 1971 when Paul Berg at 
the Stanford Medical Center decided not to do an experiment in which he 
would insert the monkey virus SV40 into E. coli. SV40 has a few genes, 
one of which has the ability to turn normal cells into cancerous ones in 
laboratory animals and human cell cultures. He wanted to unlock the 
mystery of this lethal gene which would have been a major step toward 
understanding the mechanism of cancer. 1 
As a result of the discovery of the re.s..triction enzyme that leaves a 
bit of sticky single-stranded DNA at each end and the pSC 101 plasmid 
which can take on a new gene and slip into!· coli, the number of planned 
experiments using recombinant DNA increased. Consequently, an investi-
gatory committee of molecular biologists met in 1974 and asked all re-
searchers to honor a temporary ban on certain types of recombinant DNA 
experiments deemed potentially the most dangerous: those involving 
animal tumor viruses, and those increasing toxicity in bacteria or drug 
resistance. In 1975, another committee of scientists met at Asilomar 
and voted to continue the ban on the worrisome experiments and to get the 
National Institute of Health to establish safety levels, including both 
physical and biological containment, that should be required for different 
experiments. The NIH had written the safety guidelines by the summer of 
30 
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1976. 2 Government research agencies and universities receiving govern-
ment funds have had to abide by the guidelines, but private industry has 
not, although, in general, it has voluntarily compiled. 
The guidelines were followed until 1979 when a reversal in policy for 
recombinant DNA technology was initiated by the Recombinant DNA Advisory 
Committee to NIH. It recommended that 80 to 85 percent of the work with 
recombinant DNA be exempted from the guidelines. It qualified its recom-
mendation in four ways. It said that only work using vectors that would 
not easily transfer DNA to other bacteria could be done. The worrisome 
experiments and work with more than teri liters of culture are prohibited. 
Researchers must still notify the biohazard committees at their institu-
tions of their experiments. All work must be conducted under PI safety 
conditions with an additional ban on mouth pipetting and a requirement 
that biological material must be sterilized before its disposal. 3 
On June 16, 1980, the United States Supreme Court in five to four 
decision stated that life fonns can be patented if there is a man-made 
element to them. This decision was a reversal of the Court's opinion 
from 1978 when it sent General Electric's patent application for its oil-
eating microorganism back to the Court of Customs and Patent Appeals. 
General Electric filed its application in 1972. Congress extended pat-
ent rights to plants but specifically excluded bacteria in 1970. So the 
question of patenting man-made organisms is still unresolved. 4 Approxi-
mately 114 patent applications, most of them for processes, are pending. 5 
The history of recombinant DNA demonstrates that it is controversial. 
The main objections to it have centered around it leading to a disruption 
of the evolutionary process and to the creation of new, lethal organisms. 
Specifically the reasons for anxiety are fear of the unknown, new types 
32 
of life; cancer spread by bacteria into which cancer viruses have been 
transplanted; fear that humans may become susceptible to new· diseases 
caused by organisms with genes from extremely diverse species, and fear 
that efforts to create new microbes for man's good may backfire and 
6 
change the balance of nature. 
The arguments put forth to continue the NIH guidelines included the 
fact that researchers should not assume that microorganisms are always 
handled safely, the possibility of transfer to strains indigenous in popu-
lations or already epidemic, the hazards to technical workers, the crea-
tion of a new route of exposure to cancer, and the possibility that 
bacteria making a biologically active protein might: disrupt the normal 
physiological processes in a human or animal host (i.e., Bacteria making 
the enzyme cellulase might destroy roughage in the digestive tract, there-
fore, producing chronic diarrhea.) • 7 
On the other side of the controversy are the reasons for doing re-
combinant DNA. This report has already covered the products it is 
producing, the areas of research benefitting from it, and the tremendous 
possibilities of what it can do in the future. The arguments for doing 
recombinant DNA with reduced guidelines can be understood if the epidemic 
pathogen scenario is explained. In this scenario, large ni.:unbers of E. 
coli bearing the foreign gene would have to escape from a laboratory. 
They would have to have a sufficient selective advantage over other or-
ganisms so that they can establish themselves in an ecological niche. 
Finally they would have to have some detrimental effect on some other 
. h h . 8 organism as a result oft e presence oft e foreign gene. The mutated 
~- coli used in the experiments could not fit into the scenario. Even 
if the bacteria died and released their recombinant DNA, the DNA has been 
33 
shown to be rapidly degraded when added to low concentrations of rat in-
testinal contents. 
Researchers know that the probability of contaminating a natural 
population with recombinant DNA is low if the correct materials are used 
and procedures are followed. But there are two difficulties with estimat-
ing the probability. One is the failure of estimation procedures to con-
sider the population dynamics of the contamination process. The other 
is the inability to get accurate estimates of some parameters necessary 
to compute the contamination probability. The probability of the estab-
lishment of altered bacteria is directly proportional to the fertility 
of the host-plasmid combination and to the number of plasmid-carrying 
bacteria released into the environment. It is inversely proportional to 
the host cell's death rate. Also the rate of transfer of a nonconjuga-
tive plasmid is proportional to the density of bacteria carrying a 
mobilizing, conjugative plasmid. 9 All these factors need to be consider-
ed when estimating risks. 
The question has been raised as to whether or not the creation of a 
new organism to be used as a biological weapon is prohibited by the 
Convention on the Prohibition of the Development, Production and Stock-
piling of Bacteriological and Toxin Weapons and on Their Destruction. 
The general opinion is that no treaty signatory will use recombinant DNA 
to create a weapon because any new pathogens and toxins created will not 
differ in a militarily significant way from natural ones. Even if 
genotype-targetable bioweapons (viruses or infectious nucleic acids) are 
created, they would be subject to the usual problems of operational sta-
bility and controllability, and host specificity probably could not be 
. d ·1· f lO restricted to a targete group or mi itary orce. 
34 
As can be concluded from this report, recombinant DNA is a marvelous 
technology which has created a controversy in every realm of life, moral, 
physical, and spiritual. It will be many years before the final verdict 
on it can be passed. 
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